Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004351:Drug Resistance; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D008297:Male; D016609:Neoplasms, Second Primary / Q000175:diagnosis / Q000188:drug therapy*; D012751:Sezary Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab